17 patents currently held
254 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2027. from the record
Of the 254 now held by other companies, 228 name Takeda Pharmaceutical Company Limited as their current owner, and 26 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
6
Ending by 2030
May 2027
Next term end
14
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends no later than Apr 2031 · Medium confidence
Also notable
Ends May 2030 · High confidence
Also notable
Ends Dec 2031 · High confidence
Aptamers to Tissue Factor Pathway Inhibitor and Their Use as Bleeding Disorder Therapeutics
US 8,598,327
The most cited patent in this portfolio, cited by 28 later US patents, top 25% of utility patents granted in 2013 in our data. Protection runs to 2031. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Method to Produce a Highly Concentrated Immunoglobulin Preparation for Subcutaneous Use
US 11,242,380
A family of 5 related applications built on the 2022 grant. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Stabilization of Immunoglobulins Through Aqueous Formulation with Histidine at Weak Acidic to Neutral PH
US 8,795,658
Renewed at every maintenance window since the 2014 grant; no more fees are due before its term ends in 2031.
Formerly held, still cited
Notable
Ends Mar 2027 · Medium confidence
Cited by 76 later US patents, top 10% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.
now held by Takeda Pharmaceutical Company Limited
Also notable
Ends May 2030 · Medium confidence
Cited by 9 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
now held by Takeda Pharmaceutical Company Limited
Also notable
Ends Mar 2032 · High confidence
Cited by 44 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
now held by Takeda Pharmaceutical Company Limited
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Aug 6, 2027The maintenance fee for Removal of Serine Proteases by Treatment with Finely Divided Silicon Dioxide (US 11,891,431) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
- 1 fee due Oct 21, 2027The maintenance fee for Detection of Cho-Mif Contaminations (US 10,626,166) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
- 3 of the patents on this record were granted since Aug 17, 2026
- 4 terms have ended since Aug 17, 2026
What they patent
The 5 largest of its 14 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,512,172 | Ethanol Dependence of ALPHA1 Antitrypsin C-Terminal Lys Truncation by Basic Carboxypeptidases held by Baxalta GmbH and Baxalta Incorporated In force · High confidence | In force | High confidence | |
| US 11,001,613 | Tfpi Inhibitors and Methods of Use held by Baxalta GmbH and Baxalta Incorporated In force · High confidence | In force | High confidence | |
| US 11,242,380 | Method to Produce a Highly Concentrated Immunoglobulin Preparation for Subcutaneous Use held by Baxalta GmbH and Baxalta Incorporated In force · High confidence | In force | High confidence | |
| US 11,891,431 | Removal of Serine Proteases by Treatment with Finely Divided Silicon Dioxide held by Baxalta GmbH and Baxalta Incorporated In force · Medium confidence | In force | Medium confidence | |
| US 8,461,318 | Aptamers to Tissue Factor Pathway Inhibitor and Their Use as Bleeding Disorder Thereapeutics held by Baxalta GmbH and Baxalta Incorporated In force · Medium confidence | In force | Medium confidence | |
| US 10,772,968 | Glycopolysialylation of Non-Blood Coagulation Proteins held by Baxalta Incorporated and Baxalta GmbH In force · Medium confidence | In force | Medium confidence | |
| US 8,598,327 | Aptamers to Tissue Factor Pathway Inhibitor and Their Use as Bleeding Disorder Therapeutics held by Baxalta GmbH and Baxalta Incorporated In force · Medium confidence | In force | Medium confidence | |
| US 8,293,876 | Method of Purification of Hydrophobic Proteins held by Baxalta GmbH and Baxalta Incorporated In force · High confidence | In force | High confidence | |
| US 8,795,658 | Stabilization of Immunoglobulins Through Aqueous Formulation with Histidine at Weak Acidic to Neutral PH held by Baxalta GmbH and Baxalta Incorporated In force · High confidence | In force | High confidence | |
| US 9,855,331 | Stabilization of Immunoglobulins Through Aqueous Formulation with Histidine at Weak Acidic to Neutral PH held by Baxalta GmbH and Baxalta Incorporated In force · High confidence | In force | High confidence |
Also on record, not counted in the 17: 254 patents in force now held by others · 149 patents ended · 14 applications pending · 122 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.